Form 8-K Filing Summary for BioForce Nanosciences Holdings, Inc.

This Form 8-K details significant events for BioForce Nanosciences Holdings, Inc. On April 15, 2026, Merle Ferguson sold his controlling stock interest (79.65%) in the company to Nexus Capital Investments, Inc. for $400,000. Subsequently, on June 17, 2026, Co-CEOs Steven Gagnon and John LaViolette, along with Vice-President Sasha Shapiro, resigned. The company appointed Scott Mager as a Director on June 15, 2026, bringing extensive legal and business expertise. Richard Kaiser was appointed interim CEO on June 17, 2026, while retaining his roles as CFO, Secretary, and Director. The company is also transitioning its business operations from the vitamin supplement industry to the oil and gas industry, citing numerous opportunities. The filing includes resignation letters from the former officers and details the current board composition and interim CEO appointment.